GSK

GSK has secured an exclusive global licence to develop and sell the KRAS‑EGFR antibody drug HMPL‑A830 outside China. The deal gives GSK rights to market the first‑in‑class therapy for solid tumours such as colorectal and pancreatic cancer.

GSK received FDA approval for Hibsago, an antisense oligonucleotide injection that works with existing antivirals to treat certain adults with chronic hepatitis B. The approval introduces a new treatment category in GSK’s liver disease portfolio.

Despite the Hibsago approval, GSK’s stock may still trade at a discount, raising questions about whether the share price reflects its earnings potential.

GSK reported higher revenue but a thinner net margin, yet investors still gained 20.4% including dividends. The mix of weaker profitability and strong shareholder return is noteworthy.

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Summit is expanding ivonescimab development beyond lung cancer into colorectal, bladder, kidney and other cancers, supported by early data and collaboration deals.

LONDON, October 21, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced evidence from the OPERA observational cohort spanning five years of real-world use of Cabenuva (long-acting cabotegravir and rilpivirine [CAB+RPV LA]) for HIV treatment in the U.S.

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.